Opinion|Videos|July 17, 2024
Exploring Data Outcomes From the SUNLIGHT Trial
Leading colorectal cancer specialists analyze the SUNLIGHT trial results, focusing on age-related efficacy data and its implications for treatment strategies.
Advertisement
Episodes in this series
- Briefly summarize the SUNLIGHT trial, evaluating TAS-102 ± bevacizumab in patients with mCRC (
Prager, et al. NEJM, 2023 )
- Dr Fakih: How does age impact efficacy and safety outcomes from the SUNLIGHT trial in mCRC? (
Taieb J, et al. ASCO GI 2024. Abstract 111 ) - Dr Benson: What is the impact of colorectal liver metastases (CRLM) in patients with mCRC treated with TAS-102 ± bevacizumab? (
Tabernero J, et al. ASCO 2024. Abstract 3584. )
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The EMA's CHMP recommended approval of daraxonrasib for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.
VS-7375 produced a responses previously treated metastatic pancreatic ductal adenocarcinoma.
The resubmission follows a third complete response letter issued in July 2026 that cited manufacturing deficiencies rather than efficacy or safety concerns.
The FDA granted fast track designation to opamtistomig for first-line treatment of advanced or metastatic biliary tract cancer.
A planned interim analysis of the radiopharmaceutical RYZ101 showed improved PFS by blinded independent central review vs standard of care.
The top 5 OncLive TV videos of the week.
Check out this September recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.
Advertisement
Advertisement
Trending on OncLive
1
CHMP Recommends Approval of Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer
2
Stay Ahead of ESMO 2026: See What Lung Cancer Experts Are Prioritizing
3
Lifileucel Linked to Low Rates of Post-Discharge Severe TRAEs, Readmissions in Advanced Melanoma
4
Refined ADC Development Helps Weigh Biomarker-Based Decisions and Treatment Sequencing in Gynecologic Cancers
5